Coherus Oncology (CHRS) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Coherus Oncology (CHRS) stock.

Latest Upgrades and Downgrades for Coherus Oncology Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Guggenheim	Paul Jeng	PT Cut	Buy	$10→$8
—	HC Wainwright & Co.	Swayampakula Ramakanth	Assumes	Buy	$7
—	Guggenheim	Paul Jeng	PT Cut	Buy	$12→$10
—	Guggenheim	—	Initiate	Buy	$12
—	Oppenheimer	Jay Olson	Initiate	Outperform	$10
—	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$4
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
—	UBS	Ashwani Verma	PT Cut	Neutral	$2→$1
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
—	Baird	Colleen Kusy	PT Raise	Outperform	$4→$6
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
—	Baird	Colleen Kusy	PT Cut	Outperform	$8→$4
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
—	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$4→$2
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
—	Baird	Colleen Kusy	PT Cut	Outperform	$9→$8
—	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
—	Truist Securities	Robyn Karnauskas	PT Cut	Buy	$8→$7

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $10 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

Guggenheim initiates coverage on Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Avi Kapoor

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

Maxim Group analyst Jason McCarthy upgrades Coherus Oncology (NASDAQ:CHRS) from Hold to Buy and announces $4 price target.

Benzinga Newsdesk

Coherus Oncology Inc

Coherus Oncology (CHRS) Stock Price Target 2026

Latest Upgrades and Downgrades for Coherus Oncology Stock

Coherus Oncology (CHRS) Stock Price Target 2026

Latest Upgrades and Downgrades for Coherus Oncology Stock

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

PRO
HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

PRO
HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

Coherus Oncology Inc

Coherus Oncology (CHRS) Stock Price Target 2026

Latest Upgrades and Downgrades for Coherus Oncology Stock

Coherus Oncology (CHRS) Stock Price Target 2026

Latest Upgrades and Downgrades for Coherus Oncology Stock

Analyst Ratings News

PROGuggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

PROHC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

PROGuggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PROGuggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PROMaxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PROGuggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

PROHC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

PROGuggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PROGuggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PROMaxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

PRO
HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

PRO
HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target